Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2023-11-29 Board/Management Inform…
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Director Declaration
Board/Management Information Classification · 99% confidence The document is a formal announcement disseminated via RNS (RNS Number: 0573V) from Dechra Pharmaceuticals PLC, dated November 29, 2023. The core content is a 'DIRECTOR DECLARATION' stating that Alison Platt, Non-Executive Chair, has been appointed as Chair of the Board and Non-Executive Director of Hargreaves Lansdown plc. This explicitly concerns a change in the board/senior management structure of the company (or a director's external appointment, which is often disclosed under similar rules). This aligns directly with the definition for Board/Management Information (MANG). Although it uses the RNS distribution service, the specific subject matter is not a general regulatory filing or a report announcement, but a specific personnel change.
2023-11-29 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is explicitly labeled as an 'RNS Number' notification from 'Dechra Pharmaceuticals PLC' dated '28 November 2023'. The content is structured as a 'TR-1: Standard form for notification of major holdings', detailing changes in voting rights held by JPMorgan Chase & Co. This type of filing, which reports changes in significant share ownership thresholds, corresponds directly to the Major Shareholding Notification category. Although it is distributed via RNS, the specific content dictates the 'MRQ' classification over the general 'RNS' fallback.
2023-11-28 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified by the header 'RNS Number : 9506U' and contains the standard boilerplate text indicating it is provided by RNS, the news service of the London Stock Exchange. The content itself is a 'TR-1: Standard form for notification of major holdings' detailing an acquisition of voting rights by Societe Generale, crossing a threshold. This type of filing, reporting changes in significant share ownership, directly corresponds to the Major Shareholding Notification category (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2023-11-28 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled 'FORM 8.3 - Dechra Pharmaceuticals plc' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is a mandatory disclosure required when a person or entity holds interests of 1% or more in the relevant securities of an offeror or offeree during a takeover situation. This type of filing relates to insider dealings or significant position changes during a takeover bid, which falls under the scope of M&A activity or specific regulatory disclosures related to takeovers. Since there is no specific code for 'Takeover Disclosure', and it details dealings/interests related to an offer, it is most closely related to M&A Activity (TAR). However, Form 8.3 is a specific regulatory filing related to insider interests during a takeover. Given the options, 'TAR' (M&A Activity) is the best fit as it directly concerns a takeover situation. It is not a Director's Dealing (DIRS) as the discloser is Millennium International Management LP, not necessarily a director, and the context is a takeover bid, not routine insider trading reporting. Revisiting the definitions, 'TAR' is for M&A Activity (merger proposals or takeover bids). Form 8.3 is a direct consequence of a takeover bid. Therefore, TAR is the most appropriate classification.
2023-11-28 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document explicitly states 'RNS Number : 9378U' and contains the standard boilerplate footer indicating it is provided by 'RNS, the news service of the London Stock Exchange.' The content details a 'TR-1: Standard form for notification of major holdings' regarding an acquisition/disposal of voting rights by Bank of America Corporation. This type of mandatory disclosure regarding changes in significant share ownership thresholds is a specific regulatory filing type. While it relates to shareholding changes (which could sometimes fall under MRQ), the presence of the RNS header and the specific nature of the TR-1 form strongly suggest it is a general regulatory announcement distributed via the RNS system. Since 'Major Shareholding Notification' (MRQ) is defined as 'Notification of changes in significant share ownership levels (crossing thresholds),' and this document is exactly that, MRQ is the most precise fit over the general RNS fallback.
2023-11-28 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled "FORM 8.3 - PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is used to disclose interests and dealings in securities during a takeover offer period. This type of mandatory disclosure, related to insider/significant shareholder activity during a takeover, is most closely aligned with disclosures concerning share ownership changes or insider transactions, but specifically mandated by the Takeover Code. Since there is no specific code for Takeover Code Disclosures (other than general insider trading which is DIRS, or major shareholding which is MRQ), and this relates to a specific transaction/position during a potential M&A event (Dechra Pharmaceuticals plc is the offeree), it falls under the scope of significant ownership changes related to a takeover. However, the closest fit among the provided codes for mandatory disclosures about significant share ownership changes is Major Shareholding Notification (MRQ), although this is a specific type of disclosure related to the Takeover Code. Given the context of a takeover bid (implied by the reference to the Takeover Code and an 'offeree'), this is a mandatory disclosure by a significant holder regarding their position. If we strictly follow the definitions, it is a disclosure of a position/dealing related to an offer. Since 'Takeover Activity' (TAR) is for M&A proposals/bids, and this is a disclosure *during* that process by a major holder, it is a specific regulatory filing related to the takeover. If we must choose from the list, it is a specific regulatory filing concerning share interests during a takeover. The closest general category for mandatory disclosures about share ownership changes is MRQ (Major Shareholding Notification). However, Form 8.3 is a specific disclosure required under the UK Takeover Code, which is distinct from a standard major shareholding notification (like crossing a 3% or 5% threshold under normal market rules). Given the context of the Takeover Code, it is a specific regulatory filing. Since it details positions and dealings during an offer, and is not a general M&A announcement (TAR), it is best classified as a specific regulatory filing that doesn't fit other categories, leaning towards RNS, or potentially MRQ if interpreted broadly as a major holding disclosure. Given the highly specific nature of Form 8.3, which is mandatory during a takeover, and the lack of a specific 'Takeover Disclosure' code, I will classify it as a Major Shareholding Notification (MRQ) as it details interests/dealings of a person holding over 1% in the offeree company, which is a form of major shareholding disclosure, or RNS as a fallback. I will choose MRQ as it directly relates to the size of the interest disclosed (1% or more).
2023-11-27 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.